Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors

Osteoporosis International

Volumn 23, Issue 1, 2012, Pages 277-284

  Roux, C ^a   Goldstein, J L ^b   Zhou, X ^c   Klemes, A ^c   Lindsay, R ^d  

^a université Paris Cité   (France)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c PROCTER AND GAMBLE COMPANY   (United States)

^d HELEN HAYES HOSPITAL   (United States)

Author keywords

Osteoporosis; Proton pump inhibitor; Risedronate; Upper gastrointestinal adverse events; Vertebral fracture

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PLACEBO; PROTON PUMP INHIBITOR; RISEDRONIC ACID;

AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; RISK REDUCTION; SELF REPORT; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; FEMUR NECK; GASTROINTESTINAL DISEASES; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; POLYPHARMACY; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 84857356457     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1574-5     Document Type: Article

References (23)

1. Roughead EE, McGeechan K, Sayer GP (2004) Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol 57(6):813-816 (Pubitemid 38748050)
2. Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79(2):76-83 (Pubitemid 44306164)
3. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296 (24):2947-2953 (Pubitemid 46021498)
4. de Vries F, Cooper A, Logan R, Cockle S, van Staa T, Cooper C (2007) Fracture risk in patients receiving concomitant bisphosphonate and acid-suppressive medication or bisphosphonate alone [abstract]. Osteoporos Int 18(Suppl 3):S261
5. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosisrelated fractures. CMAJ 179(4):319-326
6. Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D, Reid DM, Eastell R, Glüer CC (2009) Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 84 (1):13-19
7. de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C (2009) Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 20(12):1989-1998
8. Farina C, Gagliardi S (2002) Selective inhibition of osteoclast vacuolar H(+)-ATPase. Curr Pharma Des 8(23):2033-2048 (Pubitemid 34982169)
9. Tuukkanen J, Väänänen HK (1986) Omeprazole, a specific inhibitor of H(+)-K(+)-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 38(2):123-125 (Pubitemid 16113857)
10. Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53(1):21-25 (Pubitemid 23187327)
11. Wright MJ, Proctor DD, Insogna KL, Kerstetter JE (2008) Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 66(2):103-108 (Pubitemid 351666656)
12. Schuler A (2007) Risks versus benefits of long-term proton pump inhibitor therapy in the elderly. Geriatr Nurs 28(4):225-229
13. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118(7):778-781 (Pubitemid 40897665)
14. Richards JB, Goltzman D (2008) Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ 179 (4):306-307
15. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83-91 (Pubitemid 30099515)
16. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344-1352 (Pubitemid 29483192)
17. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 (5):333-340 (Pubitemid 32107641)
18. United States Food and Drug Administration (2010) http://www.fda.gov/. Accessed January 25, 2010
19. Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28(8):951-959
20. McGowan B, Bennett K, Barry M, Canny M (2008) The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis. Ir Med J 101(2):38-41
21. Masud T, Watts N, Lindsay R, Bainbridge V, Lange J, Steinbuch M (2008) Initiation of PPI use in postmenopausal women treated with medications for chronic diseases [abstract]. Presented at the International Osteoporosis Foundation (IOF) World Congress on Osteoporosis, Bangkok, Thailand
22. Cryer B, Bauer DC (2002) Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 77(10):1031-1043
23. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301(9):937-944